{"filings":[{"id":609357,"accession_number":"0001213900-26-060556","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2026-05-22T20:05:31+00:00","items":["3.01"],"status":"ready","headline":"Envoy Medical receives Nasdaq extension to November 16, 2026 to cure bid price deficiency","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Company received Nasdaq notice granting additional 180-day period until November 16, 2026 to meet $1.00 minimum bid price.","Initial compliance period ended May 18, 2026; company had not yet satisfied the bid price requirement.","Extension based on meeting other listing requirements and written intent to cure via reverse stock split if needed.","If not cured by new deadline, common stock may be delisted from Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":499042,"accession_number":"0001213900-26-058429","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2026-05-18T20:05:41+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Stockholders approve 6M extra shares for equity plan and 1.2M for ESPP","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["6,000,000 additional shares authorized under Amended and Restated 2023 Equity Incentive Plan (effective May 12, 2026).","1,200,000 additional shares authorized under 2023 Employee Stock Purchase Plan.","Stockholders re-elected directors Brent T. Lucas and Susan J. Kantor to Class III terms until 2029.","Ratified EisnerAmper LLP as independent auditor for fiscal year ending December 31, 2026.","Approved advisory executive compensation and issuance of warrants per Nasdaq Rule 5635(d)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96112,"accession_number":"0001213900-26-054185","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2026-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Envoy Medical completes pivotal trial enrollment for fully implanted cochlear implant; raises $30M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Completed enrollment of 56 patients in U.S. pivotal trial for Acclaim cochlear implant; first three patients reach 12-month endpoint.","Closed upsized public offering for $30M gross proceeds (up to $78M with warrants); led by Nantahala Capital and Broadfin Holdings.","Interim data from first 10 patients: CNC word recognition improved from 15.2% to 39.2%; no serious adverse events; 24-hour wear time.","Q1 2026 revenue $39k; R&D expense $3.6M; cash $25.3M as of March 31, 2026.","Appointed medical device veteran Chas McKhann to Board; expanded IP portfolio to 47 patents."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":39000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96111,"accession_number":"0001213900-26-046197","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2026-04-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Envoy Medical appoints Charles McKhann as Class I director and to Compensation Committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board size increased from 6 to 7 members; McKhann appointed to Compensation Committee.","Awarded stock options for 100,000 shares at $0.72/share, vesting monthly over 36 months.","McKhann previously CEO of Silk Road Medical (acquired by Boston Scientific) and Apollo Endosurgery (also acquired by Boston Scientific).","McKhann is independent under Nasdaq listing standards and SEC rules.","Appointment effective April 15, 2026; term expires at 2027 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109720,"accession_number":"0001213900-26-037419","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Envoy Medical dismisses Grant Thornton, appoints EisnerAmper as auditor for FY2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Grant Thornton dismissed effective March 25, 2026; EisnerAmper appointed for year ending Dec 31, 2026.","Grant Thornton's reports for 2024 and 2025 included a going concern explanatory paragraph.","No disagreements with Grant Thornton; prior material weaknesses in internal controls reported.","Engagement agreement with EisnerAmper dated March 26, 2026; no pre-approval consultations occurred."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109719,"accession_number":"0001213900-26-035483","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Envoy Medical reports FY2025 revenue $241k; extinguishes $32M debt; completes Acclaim trial enrollment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FY2025 net revenue $241k, up from $225k (YoY +$16k). No EPS given.","Extinguished over $32M of debt in 2025; cash $3.7M at year-end.","FDA approved expansion of Acclaim cochlear implant pivotal trial to final stage.","Post year-end: closed up to $78M public offering ($30M received); enrolled 56-patient pivotal trial.","IP portfolio grew to 47 patents globally."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109718,"accession_number":"0001213900-26-021116","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2026-02-27T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"Envoy Medical regains compliance with Nasdaq listing requirement after MVLS deficiency","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter confirming compliance with Listing Rule 5550(b)(2) after MVLS fell below $35M.","Discretionary panel monitor imposed for one year from February 12, 2026.","Company implemented strategic financing initiatives to strengthen balance sheet and regain compliance.","Original non-compliance notice received February 25, 2025; now resolved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109717,"accession_number":"0001213900-26-016584","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Envoy Medical closes $30.0M public offering; milestone-linked warrants could add $48.0M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds $30.0M from 75M shares/pre-funded warrants at $0.40/unit; up to $48M additional if milestone warrants exercised for cash.","Offering led by Nantahala Capital; insiders bought ~2.25M shares ($0.9M), existing shareholder Glen Taylor bought 18.75M shares ($7.5M).","Net proceeds extend cash runway into H2 2027, beyond expected PMA submission for Acclaim CI device.","Series A-1 warrants expire 30 days after PMA submission; Series A-2 warrants expire 30 days after FDA approval; exercise price $0.40.","H.C. Wainwright acted as exclusive placement agent; placement agent warrants for 3.75M shares at $0.50 per share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109716,"accession_number":"0001213900-26-014878","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Envoy Medical grants CEO 200K and CFO 15K options at $0.53","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Brent Lucas received options for 200,000 shares; Interim CFO Robert Potashnick received 15,000 shares.","Exercise price set at $0.53 per share (closing price on Feb 5, 2026).","Vesting: 25% after one year, remainder pro rata over next 36 months; options expire 10 years from award date.","Options granted under Envoy Medical's 2023 Equity Incentive Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126235,"accession_number":"0001213900-25-126032","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2025-12-29T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Envoy Medical extends Meteora warrant expiration to Dec 31, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1,125,499 Shortfall Warrants expiring Dec 31, 2025 extended to Dec 31, 2026.","Exercise price determined by VWAP formula with $1.50 per share minimum.","Warrants originally issued under April 2023 Equity Prepaid Forward Transaction.","Shares underlying warrants registered under effective S-3 (File 333-276590)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126234,"accession_number":"0001213900-25-121987","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2025-12-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Envoy Medical files investor presentation; no specific material updates disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Management will use updated investor presentation in meetings; content not fully disclosed in filing.","No new financial guidance, product milestones, or operational results provided.","Presentation contains forward-looking statements and risks; no concrete events announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126233,"accession_number":"0001213900-25-117805","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2025-12-03T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Stockholders approve warrant and share issuance under securities purchase agreement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At special meeting on Nov 26, 2025, stockholders approved issuance of warrants and related Class A common stock to comply with Nasdaq Listing Rule 5635(d).","Votes: 13,599,174 for, 243,009 against, 5,700 broker non-votes on the issuance proposal.","Adjournment proposal also approved (13,345,775 for) but not used.","Approval clears way for closing of securities purchase agreement dated Sep 22, 2025 with unnamed purchasers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126232,"accession_number":"0001213900-25-114725","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2025-11-25T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Envoy Medical receives Nasdaq deficiency notice for minimum bid price non-compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Envoy Medical on Nov 19, 2025 that common stock failed minimum $1.00 bid price for 30 consecutive business days.","Company has 180 days, until May 18, 2026, to regain compliance by closing at $1.00+ for 10 consecutive business days.","If not cured, Envoy may seek a second 180-day period by meeting other listing standards and considering a reverse stock split.","Delisting would occur if compliance not achieved; company may appeal to a Nasdaq Hearings Panel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126231,"accession_number":"0001213900-25-107898","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Envoy Medical eliminates $32M debt, gets FDA approval to expand cochlear implant trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Extinguished over $32 million in debt, strengthening balance sheet without equity issuance.","Post-quarter: FDA approved expansion of pivotal clinical trial to final stage; three patients enrolled.","Closed up to $16 million registered direct offering priced at-the-market under Nasdaq rules.","Q3 net revenue $42,000; R&D expenses $2.7M; cash $3.556M as of Sept. 30, 2025.","Expanded global patent portfolio with four new patents in U.S., Europe, and Australia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126230,"accession_number":"0001213900-25-102828","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"Envoy Medical gets Nasdaq extension until Feb 23, 2026 to meet listing requirement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq panel grants exception until Feb 23, 2026 to comply with $35M market value listing rule.","Company cites recent equity raises, debt extinguishment, and FDA approval of final stage of Acclaim cochlear implant trial.","Over 28 million shares outstanding; trading volume increased since trial expansion announcement.","Company must promptly notify Nasdaq of any events affecting compliance during the exception period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126229,"accession_number":"0001213900-25-097600","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2025-10-09T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Envoy Medical announces up to $16M registered direct offering and warrant sale","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering includes 3,007,524 shares at $1.33/share for ~$4M upfront; warrants for 9,022,572 shares at $1.33.","Warrants expire 24 months after registration effective date; potential gross proceeds total up to $16M if exercised.","H.C. Wainwright & Co. acts as exclusive placement agent with 7.5% cash fee plus 1.0% management fee.","Expected closing on October 9, 2025; net proceeds for working capital and general corporate purposes.","Placement agent receives warrants for 225,564 shares at $1.6625 per share, expiring October 2030."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126228,"accession_number":"0001213900-25-096845","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2025-10-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Envoy Medical gets FDA nod to expand pivotal Acclaim cochlear implant trial to final stage","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved expansion based on 3-month data from first 10 patients; no SAEs or UADEs reported.","Final stage will add 46 participants across 7 U.S. sites; full enrollment expected by early 2026.","Timeline shortened by 3–6 months, reducing anticipated capital need by $10–$15 million.","Preliminary data showed Acclaim can achieve effectiveness for proposed intended use in cochlear-implant-only condition.","Company believes fully implanted design addresses 95% of eligible adults who have not received a cochlear implant."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142986,"accession_number":"0001213900-25-090373","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2025-09-23T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Envoy Medical prices $2.5M registered direct offering at $1.31/share, plus warrants for up to $7.5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$2.5M from sale of 1,908,402 shares at $1.31/share; close expected Sept 23, 2025.","Concurrent private placement of warrants for 5,725,206 shares at $1.31, exercisable after stockholder approval.","Full warrant exercise could yield additional ~$7.5M in proceeds; warrants expire 24 months after stockholder approval.","Net proceeds for working capital and general corporate purposes.","H.C. Wainwright acts as placement agent; receives 7.5% cash fee and additional warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142985,"accession_number":"0001213900-25-089225","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2025-09-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Envoy Medical receives European patent for cochlear implant technology","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["European Patent No. 4338791 granted, effective Sept 17, 2025, covering implantable cochlear system with integrated components and lead characterization.","Patent covers methods for compensating variability in middle ear sensor using analog/digital signals and adjustable digital filter.","Follows recent patent issuances in the US, Australia, and Hong Kong, expanding global patent portfolio.","CEO Brent Lucas says patent strengthens position and supports mission for fully implantable hearing solutions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142984,"accession_number":"0001213900-25-086268","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2025-09-09T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Envoy Medical enters voting/warrant extension deal with 47.8% holder Glen Taylor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Taylor Parties agree to vote shares in favor of Nasdaq listing proposals through Dec 31, 2028.","GAT Warrants for 3,500,000 shares extended to Dec 31, 2028 (prev. Feb 2026–Jun 2027).","Company grants registration rights for Taylor Parties' shares; demand rights start Mar 31, 2026.","Taylor owns ~47.8% of Class A Common Stock; agreement binding on transferees.","Warrant extension and voting commitment aim to ensure Nasdaq compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142983,"accession_number":"0001213900-25-082608","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2025-08-29T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Envoy Medical faces Nasdaq delisting for failing MVLS requirement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Envoy Medical on August 26, 2025 that it failed to regain compliance with the $35M MVLS requirement within a 180-day cure period.","Company requested a hearing on August 29, 2025, which stays trading suspension until the Panel issues a decision.","Envoy cites recent debt extinguishment as a pathway to regain compliance but offers no assurance of continued listing.","Trading would have been suspended September 4, 2025 without the hearing request."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142982,"accession_number":"0001213900-25-080530","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2025-08-26T23:59:59+00:00","items":["1.02","5.02","9.01"],"status":"ready","headline":"Envoy Medical extinguishes $32M debt for $100k; Glen Taylor resigns from board","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Paid $100,000 to satisfy $32,011,552 in principal and accrued interest on three promissory notes held by GAT Funding (Glen Taylor).","Glen Taylor resigned from the board effective August 25, 2025; no disagreement with company operations.","Notes dated Feb 2024, Aug 2024, and Mar 2025 each had $10M initial principal; all obligations deemed satisfied.","Company says extinguishment strengthens balance sheet, eliminates term loan obligations without equity conversion.","Satisfaction agreement approved by independent Audit Committee; Taylor did not serve on that committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142981,"accession_number":"0001213900-25-069658","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Envoy Medical reports Q2 clinical progress, cash $5.3M; CPT codes for Esteem device effective July 1","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["All 10 Acclaim cochlear implant trial participants activated; no serious adverse events at one-month follow-up.","Five CPT codes for totally implantable active middle ear implants (Esteem) approved by AMA, effective July 1, 2025.","R&D expenses decreased to $2.485M from $2.6M; G&A increased $0.5M due to severance accrual.","Cash balance $5.3M as of June 30, 2025; net revenues increased by $10K YoY.","Subsequent to quarter end, two US and three Australian patents issued to strengthen IP portfolio."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":124000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142980,"accession_number":"0001213900-25-068760","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Envoy Medical amends warrant exercise price to weekly VWAP with $1.50 floor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment No. 3 changes exercise price of 3,209,511 outstanding Shortfall Warrants to weekly VWAP or $1.50 minimum.","New price equals greater of prior week's volume-weighted average price of COCH stock (Bloomberg) and $1.50.","Amendment is with Meteora Special Opportunity Fund I, LP and related entities.","Original warrant was issued under OTC Equity Prepaid Forward Transaction dated April 17, 2023.","No further amendment to Forward Purchase Agreement is required; prior adjustments from July 2024 remain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142979,"accession_number":"0001213900-25-061057","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2025-07-02T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Envoy Medical draws remaining $5M from GAT Funding; issues warrant for 750K shares at $1.48","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Drew $5M remaining principal under March 2025 note from GAT Funding, controlled by board member Glen Taylor.","Issued warrant for 750,000 shares of Class A common at $1.48/share closing price, exercisable for two years.","Warrant issued as commitment fee for draw; transaction is a related-party financing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161060,"accession_number":"0001213900-25-057481","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Envoy Medical appoints Robert Potashnick as Interim CFO effective June 23, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert Potashnick appointed Interim CFO via consulting agreement with Oasis Business Consulting LLC.","Compensation: $200/hour for 100-150 hours per month; term of one year.","Potashnick previously CFO of FOXO Technologies and held finance roles at UnitedHealth Group and PwC.","Consulting agreement includes confidentiality, work product assignment, and indemnification provisions.","No departure of prior CFO mentioned; appointment fills vacant role."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161059,"accession_number":"0001213900-25-050758","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Stockholders approve amendment to 2023 Equity Incentive Plan, releasing 1.5M restricted shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment removes regulatory-milestone restriction on 1,500,000 shares, making them available for issuance under the 2023 Plan.","Vote: 12,332,451 For, 658,102 Against, 20,782 Abstain, 29,189 Broker Non-Votes; amendment effective immediately.","Elected directors Janis Smith-Gomez (12,636,087 For) and Chuck Brynelsen (12,307,953 For) to Class II, term until 2028 annual meeting.","Ratified Grant Thornton LLP as independent auditor for FY2025; approved non-binding advisory vote on named executive officer compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161058,"accession_number":"0001213900-25-045109","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Envoy Medical CFO David R. Wells departs; CEO Lucas becomes interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David R. Wells ceased as CFO effective May 16, 2025, without cause.","Wells entitled to separation benefits per his August 2023 employment agreement.","CEO Brent T. Lucas will serve as interim principal financial officer.","Search for a permanent successor CFO has been initiated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161057,"accession_number":"0001213900-25-038498","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Envoy Medical Q1 revenue down $13k; enrolls 10 in pivotal CI trial; secures $10M funding","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues decreased $13k YoY to an undisclosed amount; cash balance $5.3M as of March 31, 2025.","R&D expenses rose $400k YoY due to headcount and clinical study startup for Acclaim cochlear implant.","Enrolled 10 participants in first stage of pivotal clinical trial for fully implanted Acclaim CI; 6 activated.","Secured additional $10M in funding to advance pivotal clinical trial; no serious adverse events reported.","Modifications appear to address electrical system noise observed in earlier feasibility study."],"consensus_eps_estimate":-0.3468,"consensus_eps_actual":-0.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":46000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161056,"accession_number":"0001213900-25-030747","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2025-04-11T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"Envoy Medical sets May 28, 2025 annual meeting; stockholder proposals due April 20","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual Meeting scheduled for May 28, 2025 at 3:00 p.m. CT in Vadnais Heights, Minnesota.","Record date for voting is April 8, 2025.","Deadline for stockholder proposals and director nominations is April 20, 2025 (10 days after announcement).","Meeting moved from customary October timeframe to May; new deadline set per Rule 14a-8."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179257,"accession_number":"0001213900-25-025827","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Envoy Medical FY2024 revenue down $91K; clinical trial enrollment advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues decreased $91K YoY; cash and equivalents were $5.5M as of Dec 31, 2024.","R&D expenses increased $1.2M driven by headcount for Acclaim cochlear implant pivotal study.","FDA approved pivotal trial; 6 of 10 planned first-stage participants enrolled and implanted.","New CPT codes for fully implanted middle ear implants effective July 2025; Hearing Device Coverage Clarification Act reintroduced.","G&A expenses down $438K reflecting lower professional fees post-business combination."],"consensus_eps_estimate":-0.3468,"consensus_eps_actual":-0.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":46000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179256,"accession_number":"0001213900-25-022913","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2025-03-12T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Envoy Medical obtains $10M promissory note from largest shareholder Glen Taylor","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Initial $5M funded on March 11, 2025; up to $10M available in $2.5M tranches over 2 years.","8.0% interest rate, deferred and compounding for first 2 years; 5-year term matures March 6, 2030.","Commitment fee: 375,000 warrants per $2.5M tranche; initial 750,000 warrants at $1.35/share exercise price.","Funds will support Acclaim cochlear implant pivotal clinical trial and general operations.","Glen Taylor is board member and controlling stockholder; facility unsecured with no conversion feature."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179255,"accession_number":"0001213900-25-019425","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Envoy Medical receives Nasdaq deficiency notice for low market value of listed securities","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Envoy Medical on Feb 25, 2025 that market value of listed securities fell below $35M for 31 consecutive business days.","Company has 180 days, until Aug 25, 2025, to regain compliance by having MVLS exceed $35M for 10 consecutive business days.","Failure to regain compliance could result in delisting from Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179254,"accession_number":"0001213900-25-004714","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2025-01-21T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Envoy Medical enters $15M at-the-market equity offering with Roth Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM agreement with Roth Capital Partners for up to $15M of Class A common stock.","Sales agent compensation is 3.0% of gross proceeds; $50K expense cap.","Shares sold at market prices; no minimum obligation to sell.","Offering made under effective S-3 registration filed Oct 2024.","Company may suspend sales at any time; proceeds for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195931,"accession_number":"0001213900-24-111932","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2024-12-23T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Envoy Medical extends Shortfall Warrants expiration to Dec 31, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment extends expiration date of warrants from Dec 31, 2024 to Dec 31, 2025.","Warrants cover up to 3,874,394 shares of Class A common stock at $10.46 per share.","Amendment entered with Meteora entities (MSOF, MCP, MSTO, MSC) on Dec 19, 2024.","No other warrant terms changed; prior July 2024 exercise price adjustment remains.","Resale of warrants and shares registered under effective Form S-1 since May 2, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195930,"accession_number":"0001213900-24-111279","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["1.01","3.03","9.01"],"status":"ready","headline":"Envoy Medical enters Conversion and Waiver Agreement with sponsor, modifying preferred stock terms and converting shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sponsor Anzu waives $3,733,333 in accrued dividends on Series A Preferred Stock.","Envoy waives vesting restrictions on 1,000,000 restricted shares held by Anzu.","Conversion price on Preferred Stock temporarily reduced from $11.50 to $3.63 per share through Jan 20, 2025.","Anzu converts 373,333 Preferred Stock shares into 1,028,986 shares of common stock.","Agreement executed December 20, 2024, closing same day."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195929,"accession_number":"0001213900-24-109750","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2024-12-17T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Envoy Medical draws $5M from GAT Funding note, issues warrant for 500k shares","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Drew $5M under promissory note from GAT Funding (entity controlled by board member Glen Taylor); total principal now $10M.","Issued warrant to purchase 500k shares of Class A common stock at $2.20/share as commitment fee.","Warrant expires Dec 11, 2026; exercise price equals closing price on draw date.","Note originally issued Aug 27, 2024 for up to $10M; this draw reaches maximum principal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195928,"accession_number":"0001213900-24-100544","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2024-11-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Envoy Medical stockholders elect directors, ratify auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Michael Crowe and Mona Patel elected as Class I directors; Crowe received 11,146,464 for, Patel 11,047,146 for.","Grant Thornton LLP ratified as independent auditor for FY2024 with 13,173,556 votes for.","Advisory vote on named executive officer compensation approved: 11,117,644 for, 29,673 against.","Advisory vote on frequency of executive compensation: one-year option selected (11,135,620 votes); board adopts yearly votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195927,"accession_number":"0001213900-24-097860","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Envoy Medical Q3 revenue falls to $56K; FDA OKs pivotal trial for Acclaim CI","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues $56K for Q3 2024, down 30% from $80K in Q3 2023; nine-month revenues $183K, down 17%.","Cash and cash equivalents $4.4M as of Sep 30, 2024, with R&D expenses up 47% to $2.8M due to clinical prep for Acclaim CI.","FDA approved initiation of pivotal clinical study for fully implanted Acclaim Cochlear Implant (investigational, Breakthrough Device).","AMA CPT Editorial Panel approved Category III CPT codes for totally implantable middle ear hearing devices (support for Esteem FI-AMEI reimbursement).","Bipartisan House and Senate bills introduced to change CMS classification for fully implanted middle ear hearing devices for Medicare coverage."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":183000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212206,"accession_number":"0001213900-24-076556","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2024-09-06T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"Envoy Medical sets Nov 14, 2024 annual meeting; proposal deadline Sept 20","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual Meeting set for Nov 14, 2024 at 3:00 p.m. CT in Minneapolis, MN.","Record date for stockholders entitled to vote is Sept 16, 2024.","Director nominations and stockholder proposals due by Sept 16, 2024 (10 days after announcement).","Rule 14a-8 proposals for proxy inclusion must be received by Sept 20, 2024.","Company did not hold an annual meeting in 2023; deadlines set per bylaws and SEC rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212205,"accession_number":"0001213900-24-073129","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2024-08-28T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Envoy Medical secures $10M lending facility from majority shareholder Glen Taylor; draws $5M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Unsecured Note with 8% interest, 5-year term; interest deferred for first 2 years.","Initial draw of $5M; issued warrants for 500,000 shares at $2.97 per share.","Funds to support Acclaim fully implanted cochlear implant IDE and pivotal study.","Glen Taylor is a director and controlling stockholder; facility is non-convertible.","Up to $10M available in $2.5M tranches; no prepayment penalty."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212204,"accession_number":"0001213900-24-067387","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Envoy Medical Q2 revenue $68k, cash $1.7M; Acclaim CI pivotal trial goal by end-2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Revenue $68k (Q2 2024) vs $63k prior year; revenue from two Esteem units offset by battery sales decline.","R&D expenses rose $438k to $2.6M due to increased headcount for Acclaim CI pivotal study preparation.","Three EFS participants completed 18-month follow-up; all show CIQOL improvement, no SADEs/UADEs reported.","System noise mitigations implemented; two participants used hearing aid with Acclaim for better SNR.","Company maintains goal to submit IDE in coming months and start pivotal trial by year-end 2024; commercialization targeted by end-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212203,"accession_number":"0001013762-24-003342","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Envoy Medical backs bipartisan Senate bill to classify implanted middle ear devices as prosthetics for Medicare coverage","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Senate bill S.4829 (Hearing Device Coverage Clarification Act) introduced July 29 by Klobuchar (D-MN) and Lankford (R-OK).","Bill seeks to clarify that implanted active middle ear hearing devices are prosthetics, not hearing aids, removing Medicare hearing aid exclusion.","Envoy's Esteem FI-AMEI is the only FDA-approved fully implanted active middle ear device; company expects increased competition if bill passes.","House companion legislation already introduced; Envoy believes combined efforts raise chances of enactment.","CEO Brent Lucas says bill would expand patient access and spur innovation in the segment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212202,"accession_number":"0001013762-24-003336","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Envoy Medical amends forward purchase agreement, lowers exercise price floor on 2 million warrants to $2 and $3","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment sets $2.00 floor for 1,000,000 Shortfall Warrants and $3.00 for another 1,000,000; remaining 1,874,394 warrants keep $4.00 floor.","Warrants were originally issued under Forward Purchase Agreement dated April 17, 2023 with Meteora funds.","The adjustment reduces the minimum reset price from $4.00 for 2 million warrants, potentially increasing dilution.","Company tickers: COCH (common) and COCHW (warrants) listed on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212201,"accession_number":"0001013762-24-000821","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2024-07-25T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Envoy Medical draws $2.5M from GAT Funding note, issues warrant for 250K shares","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Drew $2.5M under existing note from GAT Funding, aggregate principal now $10M.","Issued warrant to GAT for 250,000 shares at $2.25 exercise price, expiring Feb 27, 2026.","GAT is controlled by board member Glen Taylor, a related-party transaction.","Warrant issued as commitment fee for the draw; shares exempt from registration under Rule 506."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212200,"accession_number":"0001213900-24-061178","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2024-07-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Envoy Medical issues updated investor presentation for July 2024","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation includes forward-looking statements and risk factors; see Page 2.","Management intends to use presentation in meetings with current and potential investors.","No specific financial results, guidance, or material events disclosed in this filing.","Company focuses on hearing implant technology; ticker COCH."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231116,"accession_number":"0001213900-24-055739","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2024-06-25T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Envoy Medical extends warrant expiration by 6 months to Dec 31, 2024","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amendment extends 3,874,394 Shortfall Warrants expiry from June 30 to Dec 31, 2024.","Warrants have exercise price of $10.46 per share; issued to Meteora parties.","Original warrants issued Nov 27, 2023; no other changes to terms.","Registration for warrant shares already effective as of May 2, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231115,"accession_number":"0001213900-24-051511","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2024-06-11T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Envoy Medical: Dr. Haring-Smith resigns from board; Michael Crowe appointed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Whitney Haring-Smith resigned effective June 6, 2024; no disagreement.","Board appointed Michael Crowe on June 7, 2024 to fill vacancy.","Crowe receives $40k annual cash and 25,000-share option award vesting over 4 years.","Crowe is SVP Operations at Bioventus, former VP Operations at Abbott Vascular.","Envoy expects to begin pivotal clinical study for Acclaim CI later in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231114,"accession_number":"0001213900-24-046417","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Envoy Medical draws $2.5M under note from GAT Funding; issues warrant for 250K shares","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Drew $2.5M from GAT Funding LLC (controlled by director Glen Taylor); aggregate $7.5M of $10M max.","Issued warrant to purchase 250K shares of Class A common at $3.04 (closing price), expiring Feb 27, 2026.","Warrant serves as commitment fee for the draw; unregistered, exempt under Section 4(a)(2)/Reg D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231113,"accession_number":"0001213900-24-043601","cik":1840877,"company_name":"Envoy Medical, Inc.","ticker":"COCH","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Envoy Medical Q1 revenue $59K, down from $78K; draws $5M from $10M Glen Taylor loan","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $59K for Q1 2024 vs $78K in Q1 2023; decrease due to fewer battery replacement requests.","R&D expense increased $0.4M; G&A expense increased $0.7M; sales/marketing down $46K.","Cash and cash equivalents $4.9M as of March 31, 2024.","Entered $10M unsecured loan facility with Glen Taylor; initial draw $5M at 8% interest, five-year term.","All three EFS participants at Mayo completed 12-month follow-up; plan to file IDE for Acclaim CI pivotal trial later in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":59000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":53232480.564,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-05-15T23:59:59+00:00|231113"}